How much does Synexus Clinical Research Limited make?

Synexus Clinical Research Limited reported revenue of £76.4m and a loss of £9.2m in the year to 31 Dec 2022, according to its accounts filed at Companies House.

How many employees does Synexus Clinical Research Limited have?

Synexus Clinical Research Limited reported an average of 18 employees in the year to 31 Dec 2022.

Is Synexus Clinical Research Limited profitable?

No — Synexus Clinical Research Limited reported a loss of £9.2m in the year to 31 Dec 2022.

Company No. 05575991 · Incorporated 27 Sep 2005

Synexus Clinical Research Limited

Registered name: SYNEXUS CLINICAL RESEARCH LIMITED

Part of Thermo Fisher Scientific Inc. group

Synexus Clinical Research Limited made £76.4m revenue and a £9.2m loss in the year to 31 Dec 2022.

Synexus Clinical Research Limited’s revenue fell 31% to £76.4m in the year to 31 Dec 2022, with a loss of £9.2m and 18 employees. The company is classified under “other professional, scientific and technical activities” and is based in Cambridge; we hold 2 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 74909Other professional, scientific and technical activities n.e.c.

Status: Active
Location: Cambridge, East of England
Age: 21 yrs · since 2005
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The Company is a wholly owned subsidiary undertaking of, and is controlled by, Synexus Clinical Research Midco No1 Limited, a company registered in England and Wales. At 31 December 2022 the directors”

Latest accounts · year to 31 Dec 2022

Key figures

Revenue

£76.4m

Growth ▼31%

Profit

−£9.2m

Growth —

Profit margin

−12%

Gross −7.8%

Employees

Change ▼10%

Profit / employee

−£509k

Revenue/employee £4.2m

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

2 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2021	31 Dec 2022
Disclosure	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£111m	£76.4m
Cost of sales	£107m	£82.4m
Gross profit	£4.1m	−£6m
Operating profit	£1.1m	−£9.1m
Profit before tax	£259k	−£8.8m
Profit after tax	−£200k	−£9.2m
Profit (best available)	−£200k	−£9.2m
Staff costs	£2.6m	£1.7m
Employees (average)	20	18
Ratios
Profit margin	−0.2%	−12%
Gross margin	3.7%	−7.8%
Revenue per employee	£5.5m	£4.2m
Profit per employee	−£10k	−£509k
Growth (year on year)
Revenue growth	—	▼31%
Headcount growth	—	▼10%
Balance sheet — indirect signals, not revenue
Cash at bank	£9m	£37.2m
Net assets	−£2.9m	−£12.1m
Fixed assets	£11.1m	£10.9m
Current assets	£93.2m	£101m
Debtors	£11.5m	£16.6m
Deferred income	£38.1m	£65m
Source	Accounts · bulk data Dec 2023	Accounts · bulk data Dec 2023

Derived from the latest filing

How the business works

Profit margin: −12%; Profit ÷ revenue.
Gross margin: −7.8%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £4.2m; Revenue ÷ average employees.
Profit per employee: −£509k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 14.2%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 85%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 21.7%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now −£12.1m
Cash at bank: ▲313%; Now £37.2m
Headcount: ▼10%; Now 18
Deferred income: ▲70%; Now £65m
Fixed assets: ▼2%; Now £10.9m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Thermo Fisher Scientific Inc. (registered outside the UK register)ultimate parent75–100%
Thermo Fisher Scientific Powder UK Senior Holdings Limited75–100%
Thermo Fisher Scientific Powder US Holdings Limited75–100%
Wildcat Acquisition Holdings (UK) Limited75–100%
PPD International Holdings (UK) Ltd.75–100%
PPD International Investments Limited75–100%
Synexus Clinical Research Midco No 1 Limited75–100%
Synexus Clinical Research Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Subsidiaries (1)

Synexus LimitedRev. £20.6m · Profit £1.2m

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from accounts for the year to 31 Dec 2022 (profit −£9.2m), from the Companies House accounts bulk data published Dec 2023. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.